ArticleRadiation oncology (London, England)2025
Clinical implementation of deep learning-based synthetic CT for MRI-only volumetric modulated arc therapy in head and neck and pelvic cancer patients.
Article in Radiation oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic accuracy of MRI-based synthetic CT compared to conventional CT in spinal and sacroiliac disorders: a systematic review.Skeletal radiology · 2026Pooled it
- Evaluation of AI-based segmentation and synthetic CT generation for MRI-only prostate radiotherapy planning.Journal of applied clinical medical physics · 2026Article
- CT image generation from ultrashort echo time MRI for dosimetric assessment in lung cancer radiotherapy.Physics and imaging in radiation oncology · 2026Article
- Impact of dose calculation algorithm on magnetic resonance imaging-only radiotherapy for prostate and glioma.Physics and imaging in radiation oncology · 2026Article
- Phantom benchmarking for quality assurance of synthetic computed tomography in cranial magnetic resonance-only radiotherapy.Physics and imaging in radiation oncology · 2026Article
- Feasibility of Magnetic Resonance-based Synthetic Computed Tomography for Proton Dose Calculation in Prostate Cancer.Journal of medical physicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RATIONALE AND
objectiveThis study investigates the implementation of an MRI-only workflow in radiotherapy, focusing on synthetic CT (sCT) images generated through a deep learning-based commercial software to facilitate dose calculation and treatment delivery for volumetric modulated arc therapy (VMAT) in head and neck (H&N) and pelvic cancer patients.
methodsThis retrospective analysis included 33 patients (10 H&N, 9 prostate, 9 rectum, and 5 cervical cancer). All patients underwent CT and MRI for radiotherapy planning. sCT images were generated using deep learning-based MRI Planner™ software. Clinical treatment plans were initially optimized on CT and then recalculated on sCT with identical parameters. Image quality was evaluated using the dice similarity coefficient (DSC), mean error (ME), and mean absolute error (MAE). Dosimetric accuracy was assessed by comparing dose-volume histogram (DVH) differences and performing global gamma analysis (3%/2 mm to 1%/1 mm) between CT- and sCT-based plans. Treatment plan quality assurance (QA) conducted with an electronic portal imaging device (EPID) was compared between sCT and CT using global gamma analysis (3%/2 mm to 2%/2 mm). Patient set-up verification was evaluated by comparing CT-cone beam CT (CBCT) and sCT-CBCT.
resultssCT images demonstrated high accuracy, with average body DSCs of 0.99 (SD = 0.00), ME of -8.94 HU (SD = 9.50), and MAE of 67.30 HU (SD = 6.94) for H&N, and DSCs of 1.00 (SD = 0.00), ME of -8.74 HU (SD = 6.26), and MAE of 33.64 HU (SD = 3.91) for the pelvis. Lower DSCs were observed in bone, with 0.87 (SD = 0.03) in H&N and 0.88 (SD = 0.02) in pelvis. Dose differences were within 2%, with average gamma pass rates of all criteria [Formula: see text]92% for H&N and [Formula: see text]96% for pelvis, across all criteria. QA plan evaluation revealed the gamma pass rate between CT and sCT of ≤0.05% for H&N and ≤0.12% for pelvis. Mean positioning differences between CT-CBCT and sCT-CBCT were ≤0.13 mm and ≤0.06[Formula: see text] for the H&N and ≤0.17 mm and ≤0.13[Formula: see text] for the pelvis in all directions.
conclusionDeep learning-based software successfully generated accurate sCT images for both H&N and pelvic cancer patients, supporting reliable dose calculation, treatment plan QA, and patient set-up verification. This enables the potential implementation of MRI-only workflows for VMAT in H&N and pelvic cancer treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.